These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38477974)

  • 1. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
    Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
    J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
    Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
    J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
    Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
    J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    Ma M; Li M; Zhang C; Yang Z; Chen X; Lu P; Nie S; Zhang S; Ma S; Qin C
    J Med Chem; 2024 Sep; ():. PubMed ID: 39344125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
    Han X; Zhao L; Xiang W; Miao B; Qin C; Wang M; Xu T; McEachern D; Lu J; Wang Y; Metwally H; Yang CY; Kirchhoff PD; Wang L; Matvekas A; Takyi-Williams J; Wen B; Sun D; Ator M; Mckean R; Wang S
    J Med Chem; 2023 Jul; 66(13):8822-8843. PubMed ID: 37382562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
    Luo J; Chen Z; Qiao Y; Tien JC; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
    bioRxiv; 2024 May; ():. PubMed ID: 38586029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
    Xiang W; Zhao L; Han X; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Kirchhoff PD; Wang L; Matvekas A; He M; Wen B; Sun D; Wang S
    J Med Chem; 2021 Sep; 64(18):13487-13509. PubMed ID: 34473519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
    Xiang W; Zhao L; Han X; Xu T; Kregel S; Wang M; Miao B; Qin C; Wang M; McEachern D; Lu J; Bai L; Yang CY; Kirchhoff PD; Takyi-Williams J; Wang L; Wen B; Sun D; Ator M; Mckean R; Chinnaiyan AM; Wang S
    J Med Chem; 2023 Sep; 66(18):13280-13303. PubMed ID: 37683104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
    Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
    J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond.
    Hu J; Xu Y
    J Med Chem; 2024 Apr; 67(7):5272-5274. PubMed ID: 38517344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
    Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
    J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
    Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
    J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
    Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
    Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of
    Zhang B; Liu C; Yang Z; Zhang S; Hu X; Li B; Mao M; Wang X; Li Z; Ma S; Zhang S; Qin C
    J Med Chem; 2023 Aug; 66(16):11158-11186. PubMed ID: 37556600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
    Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
    J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.
    Wang C; Wang M; Wang Y; Rej RK; Aguilar A; Xu T; Bai L; Tošović J; McEachern D; Li Q; Sarkari F; Wen B; Sun D; Wang S
    J Med Chem; 2024 Aug; 67(16):14125-14154. PubMed ID: 39132814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
    Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
    Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
    Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
    Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.